NeoRx, Janssen Pharmaceutica N.V. deal

The companies will develop NERX's Avicidin cancer compound (yttrium-90 beta-emitting radionuclide) on a worldwide basis.

NERX received $10 million

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE